Experts are rapidly investigating retatrutide, a novel drug developed by Eli Lilly, as a potential breakthrough in body loss . Different than many earlier approaches, retatrutide is a dual -action agonist targeting both GLP-1 and GIP, hormones that influence appetite and blood sugar control . Initi